Everolimus, an mTORC1/2 inhibitor, in ART‐suppressed individuals who received solid organ transplantation: A prospective study-Reference-Cited by-同舟云学术

Everolimus, an mTORC1/2 inhibitor, in ART‐suppressed individuals who received solid organ transplantation: A prospective study

Published:2020-09-15 Issue:5 Volume:21 Page:1765-1779
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Henrich Timothy J.¹^ORCID,Schreiner Corinna¹²,Cameron Cheryl³,Hogan Louise E.¹,Richardson Brian³,Rutishauser Rachel L.¹,Deitchman Amelia N.⁴,Chu Simon⁵,Rogers Rodney⁵,Thanh Cassandra¹,Gibson Erica A.¹,Zarinsefat Arya⁵,Bakkour Sonia⁶,Aweeka Francesca⁴,Busch Michael P.⁶,Liegler Teri⁷,Baker Christopher⁷,Milush Jeffrey⁷,Deeks Steven G.⁷,Stock Peter G.⁵^ORCID

Affiliation:

1. Division of Experimental Medicine University of California San Francisco San Francisco CaliforniaUSA

2. Institute of Biochemistry and Molecular BiologyUlm University Ulm Germany

3. Department of Nutrition Case Western Reserve University Cleveland OhioUSA

4. Department of Clinical Pharmacy University of California San Francisco San Francisco CaliforniaUSA

5. Department of Surgery University of California San Francisco San Francisco CaliforniaUSA

6. Vitalant Research Institute San Francisco CaliforniaUSA

7. Division of HIV, Infectious Diseases & Global Medicine University of California San Francisco San Francisco CaliforniaUSA

Funder

Delaney AIDS Research Enterprise

Novartis Pharmaceuticals Corporation

amfAR, The Foundation for AIDS Research